# Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Canonical URL: https://biopharmsignal.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update
Ticker: APRE
Company: Aprea Therapeutics
Source: Aprea Therapeutics
Published: 2026-03-16 12:00 EST
Original Source URL: https://ir.aprea.com
## Summary

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to

## Article Body
Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to
## Recent Company News
- 2026-06-01 12:00 EST — [Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors](https://biopharmsignal.com/news/APRE/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumors) — Source: Aprea Therapeutics
- 2026-05-13 10:30 EST — [Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update) — Source: Aprea Therapeutics
- 2026-04-21 14:15 EST — [Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting](https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting) — Source: Aprea Therapeutics
- 2026-04-01 12:31 EST — [Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement) — Source: Aprea Therapeutics
- 2026-03-30 12:01 EST — [Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-oversubscribed-30-million-private-placement) — Source: Aprea Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)